The rapid evolution and clinical success of T-cell immunotherapies is an exciting advance in the war on cancer. This treatment modality uses engineered cells from a patient’s own immune system to target and destroy cancerous cells. Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as the most studied treatment in T-cell immunotherapy and is the basis for many ongoing clinical trials. FDA approval of the first two CAR-T therapies in 2017 provides a regulatory development framework, but optimization of CAR-T…
Wednesday, June 27, 2018 Daily Archives
Mustang Opens $7m CAR-T Manufacturing Plant
Mustang Bio has opened a CAR-T cell manufacturing facility in Massachusetts it says has capacity to treat up to 800 patients annually. Fortress Biotech-owned Mustang has several chimeric antigen receptor T cell therapies in its pipeline and has opened a facility in Worcester, Massachusetts to support their development. “Total investment into the facility, including the build out and equipment was between US$5 million (€4.3 million) and $7 million,†Mustang Bio’s chief technology officer Knut Niss told BioProcess Insider. The current…